Comparison of the Modified Low-Dose Cytarabine with 5-Day Decitabine Therapy for Elderly AML Patients Unfit for Intensive Chemotherapy
Clinical Lymphoma Myeloma and Leukemia(2016)
摘要
Classical low-dose cytarabine (LDAC; ≤ 20 mg SQ BID for 10 days) remains a standard option for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy, although long-term results were unsatisfactory. Recently, hypomethylating agents, such as decitabine and azacitidine, have been proved to have better outcomes than the classical LDAC.
更多查看译文
关键词
HDAC Inhibitors
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要